Verrica Pharmaceuticals Inc. reported its financial results for the quarter ended March 31, 2025, revealing a net loss of $9.7 million, or $0.10 per share. This represents a significant improvement compared to the net loss of $20.3 million, or $0.44 per share, reported in the same period in 2024. On a non-GAAP basis, the net loss was $7.8 million, or $0.08 per share, compared to a non-GAAP net loss of $17.8 million, or $0.38 per share, in the prior year. As of March 31, 2025, the company had $29.6 million in cash and cash equivalents. In terms of business developments, Verrica is advancing its clinical-stage pipeline, working in collaboration with Torii Pharmaceutical to initiate a global Phase 3 program for YCANTH, a treatment for common warts. Additionally, Verrica is progressing with its novel oncolytic peptide, VP-315, following promising Phase 2 trial results for the treatment of basal cell carcinoma. The company recently held an end-of-Phase 2 meeting with the FDA to help design a Phase 3 program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.